Cargando…
Vulvar leukoplakia: therapeutic options
Vulvar leukoplakia is not a histological diagnosis and involves several diseases. Most commonly, these are vulvar lichen sclerosus and squamous cell hyperplasia of the vulva. These two conditions have similar aetiology, clinical presentation and treatment but different histopathological changes. The...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573333/ https://www.ncbi.nlm.nih.gov/pubmed/33100949 http://dx.doi.org/10.5114/pm.2020.99570 |
_version_ | 1783597419381915648 |
---|---|
author | Yordanov, Angel Tantchev, Latchezar Kostov, Stoyan Slavchev, Stanislav Strashilov, Strahil Vasileva, Polina |
author_facet | Yordanov, Angel Tantchev, Latchezar Kostov, Stoyan Slavchev, Stanislav Strashilov, Strahil Vasileva, Polina |
author_sort | Yordanov, Angel |
collection | PubMed |
description | Vulvar leukoplakia is not a histological diagnosis and involves several diseases. Most commonly, these are vulvar lichen sclerosus and squamous cell hyperplasia of the vulva. These two conditions have similar aetiology, clinical presentation and treatment but different histopathological changes. They both lead to significant impairment of quality of life, risk of malignancy, as well as recurrence after treatment. Treatment of these conditions includes topical corticosteroids as a first-line therapy, but they have their side effects and not all patients are receptive to this therapy. This requires the use of alternative therapeutic options such as topical calcineurin inhibitors, topical and systemic retinoids, other steroid creams, various destructive techniques and, as a last resort, surgical removal of affected tissues. Surgical treatment should be avoided, despite the malignant potential, because of recurrence risk in both diseases New therapeutic approaches are coming into effect in gynaecological practice due to potential risks of the above-mentioned methods. Platelet-rich plasma therapy, ablative and non-ablative laser treatment, and new topical medicines, are some of the new options applied to improve the efficacy of treatment avoiding the side effects of conventional medications. A number of them are still in their initial phase of application and time will tell their effectiveness. |
format | Online Article Text |
id | pubmed-7573333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-75733332020-10-23 Vulvar leukoplakia: therapeutic options Yordanov, Angel Tantchev, Latchezar Kostov, Stoyan Slavchev, Stanislav Strashilov, Strahil Vasileva, Polina Prz Menopauzalny Review Paper Vulvar leukoplakia is not a histological diagnosis and involves several diseases. Most commonly, these are vulvar lichen sclerosus and squamous cell hyperplasia of the vulva. These two conditions have similar aetiology, clinical presentation and treatment but different histopathological changes. They both lead to significant impairment of quality of life, risk of malignancy, as well as recurrence after treatment. Treatment of these conditions includes topical corticosteroids as a first-line therapy, but they have their side effects and not all patients are receptive to this therapy. This requires the use of alternative therapeutic options such as topical calcineurin inhibitors, topical and systemic retinoids, other steroid creams, various destructive techniques and, as a last resort, surgical removal of affected tissues. Surgical treatment should be avoided, despite the malignant potential, because of recurrence risk in both diseases New therapeutic approaches are coming into effect in gynaecological practice due to potential risks of the above-mentioned methods. Platelet-rich plasma therapy, ablative and non-ablative laser treatment, and new topical medicines, are some of the new options applied to improve the efficacy of treatment avoiding the side effects of conventional medications. A number of them are still in their initial phase of application and time will tell their effectiveness. Termedia Publishing House 2020-10-02 2020-09 /pmc/articles/PMC7573333/ /pubmed/33100949 http://dx.doi.org/10.5114/pm.2020.99570 Text en Copyright © 2020 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Review Paper Yordanov, Angel Tantchev, Latchezar Kostov, Stoyan Slavchev, Stanislav Strashilov, Strahil Vasileva, Polina Vulvar leukoplakia: therapeutic options |
title | Vulvar leukoplakia: therapeutic options |
title_full | Vulvar leukoplakia: therapeutic options |
title_fullStr | Vulvar leukoplakia: therapeutic options |
title_full_unstemmed | Vulvar leukoplakia: therapeutic options |
title_short | Vulvar leukoplakia: therapeutic options |
title_sort | vulvar leukoplakia: therapeutic options |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573333/ https://www.ncbi.nlm.nih.gov/pubmed/33100949 http://dx.doi.org/10.5114/pm.2020.99570 |
work_keys_str_mv | AT yordanovangel vulvarleukoplakiatherapeuticoptions AT tantchevlatchezar vulvarleukoplakiatherapeuticoptions AT kostovstoyan vulvarleukoplakiatherapeuticoptions AT slavchevstanislav vulvarleukoplakiatherapeuticoptions AT strashilovstrahil vulvarleukoplakiatherapeuticoptions AT vasilevapolina vulvarleukoplakiatherapeuticoptions |